TCM formula granules are granules made of single TCM decoction pieces by water extraction, separation, concentration, drying and granulation.
Under the guidance of TCM theory, they are formulated in accordance with TCM clinical prescriptions and used for brewing by patients
.
In recent years, policies favoring traditional Chinese medicine formula granules have been continuously released, including exemption from "zero addition", the introduction of national standards, and full liberalization.
Many institutions predict that the market size of traditional Chinese medicine formula granules will reach 100 billion yuan in 2030, which also attracts Many pharmaceutical companies have deployed this track
.
According to data from Debon Securities, the current traditional Chinese medicine formula granule market presents a pattern of "one super and many strong", among which Guangdong Yifang (Chinese traditional medicine), Jiangyin Tianjiang (Chinese traditional Chinese medicine), China Resources Sanjiu, Hongri Pharmaceutical, Sichuan New Green The six pilot companies, Pharma and Peili (Nanning), still occupy most of the market share
.
In addition, there are dozens of listed companies on the track, including Jilin Aodong, Essence Pharmaceuticals, Zuoli Pharmaceuticals, etc.
, which have clearly laid out traditional Chinese medicine formula granules
.
The industry believes that although the market prospect of traditional Chinese medicine formula granules is good, the industry standards are also constantly improving, and the future supervision will be stricter.
It is expected that the leading traditional Chinese medicine formula granule companies are expected to continue to benefit, leaving little market space for latecomers.
, but companies also have the opportunity to fight
.
In order to enhance their competitiveness, many entrants have taken action
.
For example, on June 29 this year, Yibai Pharmaceutical announced that, by consensus, the company plans to jointly increase the capital of Yibai Formula Granules, a wholly-owned subsidiary of the company, with the Guizhou Agricultural Development Fund to invest in the construction of the company's entire industry chain project of traditional Chinese medicine formula granules
.
According to the announcement at that time, Yibai Pharmaceutical planned to increase the capital of Yibai Formula Granules at a price of 99.
8539 million yuan in kind and equity
.
At the same time, the Guizhou Agricultural Development Fund plans to increase the capital of Yibai Formula Granules with 80 million yuan in cash
.
The two parties will give play to their respective advantages in the field of formula granules, jointly invest in the construction of the whole industry chain project of traditional Chinese medicine formula granules integrating medicinal material planting, harvesting, production and processing, build the company's core competitiveness in the field of traditional Chinese medicine formula granules, and enhance the company's comprehensive competitiveness.
Achieve the company's sustainable development strategic goals
.
After the completion of this capital increase, the registered capital of Yibai Formula Granules will be increased from RMB 20 million to nearly RMB 200 million, the company's shareholding in Yibai Formula Granules will be changed to 59.
97%, and the Guizhou Agricultural Development Fund will hold 40.
03% of Yibai Formula Granules 's equity
.
On August 27, Yibai Pharmaceutical disclosed the company's progress announcement on the capital increase and share expansion of its subsidiary, Guizhou Yibai Traditional Chinese Medicine Formula Granules Pharmaceutical Co.
,
Ltd.
The new progress announcement shows that according to the agreement on capital increase and share expansion, on June 30, 2022, Yibai Formula Granules received an equity capital increase of RMB 80 million from the Guizhou Agricultural Development Fund
.
On August 26, 2022, Yibai Formula Granules obtained the "Business License" issued by the Municipal Supervision Bureau of Guanshanhu District, Guiyang City
.
As of the disclosure date of this announcement, all funds for the capital increase and share expansion have been received, and the industrial and commercial registration procedures for the equity change of Yibai Formula Granules have been completed.
The company will enjoy the shareholders' rights and obligations of Yibai Formula Granules in accordance with the shareholding ratio
.
In addition to the impact of this capital increase and share expansion on the company, Yibai Pharmaceutical stated that after the completion of this capital increase and share expansion, Yibai Formula Granules will change from a wholly-owned subsidiary of the company to a holding subsidiary of the company
.
This capital increase and share expansion will help to further improve the company's entire pharmaceutical industry chain layout, enhance the company's core competitiveness, and achieve the company's sustainable development with the help of the agricultural development fund and its industrial resource advantages
.
According to the company’s data, Yibai Pharmaceutical is a new drug research and development company integrating the research, development, production and sales of new drugs.
Its business involves modern Chinese medicine, chemical medicine, biological medicine, health care products and other fields
.
As of the close on August 26, Yibai Pharmaceutical closed at 5.
37 yuan, up 4% from last week's 5.
16 yuan
.
![2,4,8,10-Tetraoxa-3,9-dithiaspiro[5.5]undecane, 3,3,9,9-tetraoxide](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
